+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Tumor Therapeutics Market - Global Forecast 2026-2032- Product Image
Brain Tumor Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Brain Tumor Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011114
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Tumor Therapeutics Market is projected to reach USD 3.87 Billion in 2026. It is expected to continue growing at a CAGR of 10.10%, reaching USD 6.99 Billion by 2032.

Brain tumor therapeutics are entering a more precise era as neuro-oncology shifts from histology-led treatment to molecularly defined care. The global burden remains clinically urgent: IARC GLOBOCAN 2022 reported more than 320,000 new cancers of the brain and central nervous system worldwide, while glioblastoma continues to carry a median survival of roughly 15 months with standard surgery, radiotherapy, and temozolomide-based chemotherapy.

Growth in the brain tumor therapeutics market is being shaped by IDH-targeted drugs, immuno-oncology combinations, antibody-drug conjugates, radiopharmaceutical research, tumor treating fields, and improved drug delivery across the blood-brain barrier. FDA approval of vorasidenib in 2024 for IDH-mutant grade 2 glioma strengthened confidence in biomarker-driven neuro-oncology pipelines and reinforced the strategic importance of precision medicine in brain cancer treatment.

Transformative Shifts in Brain Tumor Therapeutics

The competitive landscape is moving from broad cytotoxic treatment toward integrated regimens built around molecular profiling, maximal safe resection, advanced radiotherapy, and targeted systemic therapy. The 2021 WHO Classification of CNS Tumors made molecular markers central to diagnosis, increasing demand for next-generation sequencing, IDH testing, MGMT promoter methylation assessment, and 1p/19q codeletion analysis.

Transformative shifts also include novel trial designs, decentralized imaging review, adaptive platform studies, and greater use of real-world evidence. Because many brain tumors are rare or biologically heterogeneous, sponsors are prioritizing biomarker-enriched cohorts, companion diagnostics, and endpoints that capture progression-free survival, neurocognitive function, corticosteroid use, seizure control, and quality of life.

Cumulative Impact of Artificial Intelligence on Neuro-Oncology

Artificial intelligence is becoming a practical accelerator across the brain tumor care pathway. In radiology, AI-enabled segmentation and volumetric assessment can support more consistent MRI interpretation, tumor burden tracking, edema evaluation, and radiotherapy planning; in pathology, digital image analysis can help quantify morphology and guide molecular testing workflows.

AI is also influencing drug discovery and clinical development by supporting target prioritization, blood-brain barrier permeability modeling, patient stratification, synthetic control exploration, and trial-site selection. The highest-value applications are those validated against clinical outcomes, integrated into regulated workflows, and governed with transparent data provenance, bias monitoring, cybersecurity safeguards, and physician oversight.

Key Regional Insights Across Brain Tumor Therapeutics

North America remains a leading innovation hub for brain tumor therapeutics, supported by the U.S. National Cancer Institute, major academic cancer centers, high clinical trial density, and established reimbursement pathways for advanced diagnostics and oncology drugs. The United States continues to shape evidence generation through precision oncology trials and regulatory pathways for orphan and breakthrough therapies, while Canada contributes through neuro-oncology networks and publicly funded cancer care, although provincial reimbursement timelines can influence access.

Europe benefits from coordinated research under European Union frameworks, strong neurosurgery and radiotherapy infrastructure in Germany, France, Italy, Spain, and the United Kingdom, and EMA pathways for orphan and advanced therapies. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase oncology trial participation, genomic testing capacity, advanced imaging adoption, and local biopharma investment. Latin America is seeing rising demand through major referral centers in Brazil and Mexico, but affordability, molecular diagnostic access, and timely radiotherapy availability remain constraints. The Middle East is strengthening tertiary oncology care through GCC health-system investment, international clinical partnerships, and specialty hospital expansion, while Africa faces the greatest infrastructure gaps in MRI access, neurosurgical capacity, pathology services, and high-cost therapy availability, making workforce development and diagnostic capacity building essential.

Key Group Insights for Global Neuro-Oncology Growth

Within the G7, the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom anchor much of the global clinical evidence base for brain tumor therapeutics through mature oncology systems, academic trial networks, advanced imaging infrastructure, and regulatory experience with orphan drugs. NATO economies overlap with many of these strengths, especially in advanced imaging, cybersecurity for health data, biomanufacturing resilience, and cross-institutional research collaboration.

The European Union is important for harmonized regulatory science, cross-border research, health technology assessment, and rare cancer collaboration, particularly where multi-country evidence is needed for small neuro-oncology populations. BRICS countries are increasingly relevant because of large patient populations, expanding domestic pharmaceutical capabilities, growing genomic medicine programs, and broader access initiatives in tertiary oncology centers. ASEAN markets are strengthening specialty oncology infrastructure through referral hospitals, private health investment, and regional clinical collaboration, while GCC countries are expanding high-acuity cancer care, molecular diagnostics, and medical tourism capabilities; however, access across both groups often depends on reimbursement reform, trained neuro-oncology teams, and availability of molecular diagnostics.

Key Country Insights in Brain Tumor Therapeutics

The United States leads in venture funding, FDA oncology approvals, precision diagnostics, academic trial enrollment, and adoption of advanced neuroimaging, while Canada offers strong population-based cancer registries, organized care pathways, and publicly funded access frameworks. Mexico and Brazil are important Latin American markets where tertiary centers are advancing neurosurgery, radiotherapy, and neuro-oncology services, but affordability, molecular testing coverage, and uneven regional access remain key constraints.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist neurosurgery, radiotherapy capacity, molecular pathology, and clinical research activity, with Germany and France particularly strong in hospital-based oncology infrastructure and the United Kingdom supported by national cancer research networks. Russia maintains major oncology centers and neurosurgical expertise, but access and supply-chain complexity can affect availability of advanced therapies and diagnostics. China is scaling domestic innovation, genomic testing, and oncology trial activity; India has high unmet need and expanding private oncology infrastructure, though access varies widely by region and payer type; Japan emphasizes regulatory rigor, elderly patient care, and high-quality diagnostics; South Korea is strong in digital health, imaging technology, and oncology research; and Australia contributes through high-quality clinical trials, rare cancer networks, and coordinated specialist care despite geographic access challenges.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined development strategies, including IDH mutation, MGMT methylation, TERT promoter, EGFR alteration, BRAF mutation, NTRK fusion, H3 K27 alteration, and 1p/19q codeletion status where clinically relevant. Early alignment between therapeutic programs, companion diagnostics, tissue requirements, liquid biopsy feasibility, and MRI-based response criteria can reduce development risk.

Organizations should also invest in blood-brain barrier delivery science, rational combination strategies with radiotherapy and immunotherapy, equitable trial recruitment, pediatric and adult evidence planning where appropriate, and real-world evidence systems. Partnerships with academic neuro-oncology centers, imaging core labs, patient advocacy groups, regulators, and payers can improve enrollment, evidence quality, patient access, and launch readiness without relying on speculative market assumptions.

Research Methodology

This executive summary is based on triangulation of publicly available clinical, regulatory, epidemiological, and scientific sources, including IARC GLOBOCAN cancer statistics, WHO CNS tumor classification updates, FDA and EMA public records, peer-reviewed neuro-oncology literature, clinical trial registries, treatment guidelines, and health technology assessment materials.

The research approach emphasizes verified evidence over speculative market claims. Insights were assessed through disease burden, treatment standards, pipeline direction, biomarker adoption, regional care infrastructure, reimbursement context, regulatory activity, and technology readiness, with particular attention to data consistency, source credibility, and clinical relevance for brain tumor therapeutics.

Conclusion: Precision, Access, and Evidence Will Define Leadership

Brain tumor therapeutics remain one of oncology’s most challenging segments because aggressive biology, tumor heterogeneity, immune suppression, and the blood-brain barrier limit treatment durability. Even so, the field is advancing through molecular diagnosis, targeted therapy, improved imaging, precision radiotherapy, tumor treating fields, and smarter clinical trial models.

The organizations best positioned for sustainable leadership will combine rigorous science with practical access strategies. Stakeholders that validate differentiated mechanisms, integrate AI responsibly, prove clinically meaningful outcomes, expand diagnostic readiness, and collaborate across global neuro-oncology ecosystems can help improve survival, preserve neurological function, and enhance quality of life for patients with brain tumors.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Brain Tumor Therapeutics Market, by Product Type
7.1. Introduction
7.2. Devices
7.2.1. Imaging Equipment
7.2.2. Radiation Equipment
7.2.3. Surgical Instruments
7.3. Medicine
8. Brain Tumor Therapeutics Market, by Therapeutic Approach
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Antimetabolites
8.2.3. Plant Alkaloids
8.3. Immunotherapy
8.3.1. CAR T
8.3.2. Checkpoint Inhibitors
8.3.3. Vaccines
8.4. Radiotherapy
8.4.1. Brachytherapy
8.4.2. External Beam Radiotherapy
8.4.3. Stereotactic Radiosurgery
8.5. Surgery
8.5.1. Craniotomy
8.5.2. Stereotactic Surgery
9. Brain Tumor Therapeutics Market, by Tumor Type
9.1. Introduction
9.2. Astrocytoma
9.3. Glioblastoma
9.4. Meningioma
10. Brain Tumor Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Brain Tumor Therapeutics Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Brain Tumor Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Brain Tumor Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Brain Tumor Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. AIVITA Biomedical, Inc.
16.3. Amgen Inc.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. Bio-Rad Laboratories, Inc.
16.7. Bristol-Myers Squibb Company
16.8. CNS Pharmaceuticals, Inc.
16.9. Curtana Pharmaceuticals
16.10. Dr. Reddy’s Laboratories Ltd.
16.11. Eisai Inc.
16.12. Eli Lilly and Company
16.13. F. Hoffmann-La Roche AG
16.14. GE HealthCare Technologies Inc.
16.15. Gentech, Inc.
16.16. GlaxoSmithKline PLC
16.17. Illumina, Inc.
16.18. Johnson & Johnson Services, Inc.
16.19. Merck KGaA
16.20. Novartis AG
16.21. Novocure GmbH
16.22. Pfizer Inc.
16.23. Qiagen N.V.
16.24. Sanofi S.A.
16.25. Siemens Healthcare GmbH
16.26. Y-mAbs Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RADIATION EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RADIATION EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RADIATION EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CAR T MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CAR T MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CAR T MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CRANIOTOMY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CRANIOTOMY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CRANIOTOMY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL STEREOTACTIC SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL STEREOTACTIC SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL STEREOTACTIC SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ASTROCYTOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ASTROCYTOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ASTROCYTOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GLIOBLASTOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GLIOBLASTOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GLIOBLASTOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MENINGIOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MENINGIOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MENINGIOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 129. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 131. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 132. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 133. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 134. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 135. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 136. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 137. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 138. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 153. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 154. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 155. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 156. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 157. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 158. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 159. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 165. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 166. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 167. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 168. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 169. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 170. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 171. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 172. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 176. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 177. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 178. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 179. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 180. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 181. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 182. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 183. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 199. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 200. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 201. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 202. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 203. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 204. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 209. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 210. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 211. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 212. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 213. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 214. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 215. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 216. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 220. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 221. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 222. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 223. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 224. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 225. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 226. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 227. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 243. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 244. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 245. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 246. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 247. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 248. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 249. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 250. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 254. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 255. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 256. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 257. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 258. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 259. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 260. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 287. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 288. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 289. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 290. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 291. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 292. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 293. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 294. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 299. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 300. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 301. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 302. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 303. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 304. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 305. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 306. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 320. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 321. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 322. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 323. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 324. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 325. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 326. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 327. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 328. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 331. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 332. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 333. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 334. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 335. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 336. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 337. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 339. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 341. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 342. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 343. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 344. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 345. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 346. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
TABLE 347. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 348. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 349. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 350. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 352. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE,

Companies Mentioned

  • AbbVie Inc.
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.87 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.99 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Brain Tumor Diagnosis & Therapeutics Market - Global Forecast 2026-2032 - Product Image

Brain Tumor Diagnosis & Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Brain Tumor Diagnosis & Treatment Market - Global Forecast 2026-2032 - Product Image

Brain Tumor Diagnosis & Treatment Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Brain Tumor Diagnosis and Treatment - Global Strategic Business Report - Product Image

Brain Tumor Diagnosis and Treatment - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From
Brain Tumor Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Brain Tumor Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Brain Tumor Therapeutics - Global Strategic Business Report - Product Image

Brain Tumor Therapeutics - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.